Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px
Organisation › Details

Evotec AG (FSE: EVT, TecDAX)

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. *

 

Period Start 2005-06-24 renamed
  Group Evotec (Group)
  Predecessor Evotec OAI AG
Products Industry drug discovery technology
  Industry 2 drug discovery services
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Spillner, Enno (Evotec 201607– CFO before 4SC CEO + CFO before BioM Venture Capital GmbH)
     
Region Region Hamburg
  Country Germany
  Street 7 Essener Bogen
  City 22419 Hamburg
  Tel +49-40-56081-0
    Address record changed: 2018-07-24
     
Basic data Employees F: 1,001 to 5,000 (2017-12-31)
  Currency EUR
  Annual sales 257,630,000 (revenues, consolidated (2017) 2017-12-31)
  Profit 23,999,000 (2017-12-31)
  Cash 67,017,000 (2017-12-31)
     
    * Document for �About Section�: Evotec AG. (5/31/18). "Press Release: Evotec Forms Academic Bridge »LAB591« with Arix Bioscience and Fred Hutchinson Cancer Research Center". Hamburg.
     
   
Record changed: 2018-12-04

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for Evotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px




» top